Literature DB >> 18623110

Aberrant crypt foci as precursors in colorectal cancer progression.

Frank A Orlando1, Dongfeng Tan, Juan D Baltodano, Thaer Khoury, John F Gibbs, Victor J Hassid, Bestoun H Ahmed, Sadir J Alrawi.   

Abstract

Colorectal cancer progression originates when accumulated genetic and epigenetic alterations cause genomic instability and a malignant phenotype. Subsequent molecular pathway deregulation leads to histopathologic changes that are clinically evident as aberrant crypt foci (ACF) and visualized by high-magnification chromoscopic colonoscopy. ACF are biomarkers of increased colorectal cancer risk, particularly those with dysplastic features. Genetic profiling using genomic instability, loss of heterozygosity, and methylation analysis has revealed a minority population of ACF genotypically analogous to cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18623110      PMCID: PMC3971525          DOI: 10.1002/jso.21106

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  99 in total

1.  Large-bowel cancer in Hawaiian Japanese.

Authors:  W Haenszel; J W Berg; M Segi; M Kurihara; F B Locke
Journal:  J Natl Cancer Inst       Date:  1973-12       Impact factor: 13.506

2.  Evolution of cancer of the colon and rectum.

Authors:  B C Morson
Journal:  Cancer       Date:  1974-09       Impact factor: 6.860

3.  Precancerous and early malignant lesions of the large intestine.

Authors:  B C Morson
Journal:  Br J Surg       Date:  1968-10       Impact factor: 6.939

4.  Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma.

Authors:  Xing Cui; Yoshio Shirai; Toshifumi Wakai; Naoyuki Yokoyama; Seishiro Hirano; Katsuyoshi Hatakeyama
Journal:  Hum Pathol       Date:  2004-10       Impact factor: 3.466

5.  Allelotype of colorectal carcinomas.

Authors:  B Vogelstein; E R Fearon; S E Kern; S R Hamilton; A C Preisinger; Y Nakamura; R White
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

6.  Clinical importance of DNA content in rectal cancer measured by flow cytometry.

Authors:  J R Jass; K Mukawa; H S Goh; S B Love; D Capellaro
Journal:  J Clin Pathol       Date:  1989-03       Impact factor: 3.411

7.  Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings.

Authors:  R P Bird
Journal:  Cancer Lett       Date:  1987-10-30       Impact factor: 8.679

8.  Aberrant crypts: potential preneoplastic lesions in the murine colon.

Authors:  E A McLellan; R P Bird
Journal:  Cancer Res       Date:  1988-11-01       Impact factor: 12.701

Review 9.  The search for the causes of breast and colon cancer.

Authors:  W Willett
Journal:  Nature       Date:  1989-03-30       Impact factor: 49.962

10.  Aberrant crypts: putative preneoplastic foci in human colonic mucosa.

Authors:  T P Pretlow; B J Barrow; W S Ashton; M A O'Riordan; T G Pretlow; J A Jurcisek; T A Stellato
Journal:  Cancer Res       Date:  1991-03-01       Impact factor: 12.701

View more
  14 in total

1.  Precancerous ACF induction affects their regional distribution forsaking oxidative stress implication in 1,2-dimethylhydrazine-induced colon carcinogenesis model.

Authors:  Hichem Moulahoum; Andras-Laszlo Nagy; Bahia Djerdjouri; Simona Clichici
Journal:  Inflammopharmacology       Date:  2017-07-21       Impact factor: 4.473

2.  Proximal Aberrant Crypt Foci Associate with Synchronous Neoplasia and Are Primed for Neoplastic Progression.

Authors:  David A Drew; Allen Mo; James J Grady; Richard G Stevens; Joel B Levine; Bruce M Brenner; Joseph C Anderson; Faripour Forouhar; Michael J O'Brien; Thomas J Devers; Daniel W Rosenberg
Journal:  Mol Cancer Res       Date:  2017-12-08       Impact factor: 5.852

3.  Fish Oil Contaminated with Persistent Organic Pollutants Induces Colonic Aberrant Crypt Foci Formation and Reduces Antioxidant Enzyme Gene Expression in Rats.

Authors:  Mee Young Hong; Eunha Hoh; Brian Kang; Rebecca DeHamer; Jin Young Kim; Jan Lumibao
Journal:  J Nutr       Date:  2017-06-28       Impact factor: 4.798

4.  A novel clinically relevant animal model for studying galectin-3 and its ligands during colon carcinogenesis.

Authors:  Marcelo Hill; Daniel Mazal; Verónica Andrea Biron; Laura Pereira; Luis Ubillos; Edgardo Berriel; Hafiz Ahmed; Teresa Freire; Mariella Rondán; Gerardo R Vasta; Fu-Tong Liu; María Mercedes Iglesias; Eduardo Osinaga
Journal:  J Histochem Cytochem       Date:  2010-03-02       Impact factor: 2.479

5.  Identification of key candidate genes and pathways associated with colorectal aberrant crypt foci-to-adenoma-to-carcinoma progression.

Authors:  Setareh Fayazfar; Afsaneh Arefi Oskouie; Akram Safaei; Hakimeh Zali; Ehsan Nazemalhosseini Mojarad
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2021

6.  Transcriptomic and proteomic insights into patulin mycotoxin-induced cancer-like phenotypes in normal intestinal epithelial cells.

Authors:  Neha Singh; Indra Dev; Saurabh Pal; Sanjeev Kumar Yadav; Mohammed M Idris; Kausar Mahmood Ansari
Journal:  Mol Cell Biochem       Date:  2022-02-12       Impact factor: 3.396

7.  Aberrant crypt focus and fragile histidine triad protein in sporadic colorectal carcinoma.

Authors:  Kim Vaiphei; Aruna Rangan; Rajinder Singh
Journal:  World J Gastrointest Oncol       Date:  2012-12-15

Review 8.  Azoxymethane-induced rat aberrant crypt foci: relevance in studying chemoprevention of colon cancer.

Authors:  Jayadev Raju
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

9.  Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium.

Authors:  Xi Zhang; Sharon X Liang; Lin Jia; Ning Chen; Oluwole Fadare; Peter E Schwartz; Beihua Kong; Wenxin Zheng
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

Review 10.  Morphological and molecular alterations in 1,2 dimethylhydrazine and azoxymethane induced colon carcinogenesis in rats.

Authors:  Martina Perše; Anton Cerar
Journal:  J Biomed Biotechnol       Date:  2010-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.